

---

# SECURITIES AND EXCHANGE COMMISSION

## Washington, D.C. 20549

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)\*

Inhibikase Therapeutics, Inc.

(Name of Issuer)

Common Stock, \$0.001 par value per share

(Title of Class of Securities)

45719W205

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

---

---

## SCHEDULE 13G

CUSIP No.

45719W205

1	Names of Reporting Persons Sands Capital Life Sciences Pulse Fund II, L.P.
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)
3	Sec Use Only
4	Citizenship or Place of Organization CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power
	6	Shared Voting Power 13,018,965.00
	7	Sole Dispositive Power
	8	Shared Dispositive Power 13,018,965.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 13,018,965.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9) 10.8 %	
12	Type of Reporting Person (See Instructions) PN	

**Comment for Type of Reporting Person:** The percentages reported in this Schedule 13G are based upon 120,899,650 Shares outstanding as of November 20, 2025 (according to the Issuer's 424B5 Prospectus Supplement as filed with the Securities and Exchange Commission on November 21, 2025).

## SCHEDULE 13G

CUSIP No.	45719W205
-----------	-----------

1	Names of Reporting Persons Sands Capital Alternatives, LLC	
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power
	6	Shared Voting Power 13,018,965.00
	7	Sole Dispositive Power
	8	Shared Dispositive Power 13,018,965.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 13,018,965.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	

11	Percent of class represented by amount in row (9) 10.8 %
12	Type of Reporting Person (See Instructions) OO

**Comment for Type of Reporting Person:** The percentages reported in this Schedule 13G are based upon 120,899,650 Shares outstanding as of November 20, 2025 (according to the Issuer's 424B5 Prospectus Supplement as filed with the Securities and Exchange Commission on November 21, 2025).

## SCHEDULE 13G

CUSIP No.	45719W205
-----------	-----------

1	Names of Reporting Persons SANDS FRANK M.	
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization UNITED STATES	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power
	6	Shared Voting Power 13,018,965.00
	7	Sole Dispositive Power
	8	Shared Dispositive Power 13,018,965.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 13,018,965.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9) 10.8 %	
12	Type of Reporting Person (See Instructions) HC, IN	

**Comment for Type of Reporting Person:** The percentages reported in this Schedule 13G are based upon 120,899,650 Shares outstanding as of November 20, 2025 (according to the Issuer's 424B5 Prospectus Supplement as filed with the Securities and Exchange Commission on November 21, 2025).

## SCHEDULE 13G

### Item 1.

(a) Name of issuer:

Inhibikase Therapeutics, Inc.

**(b) Address of issuer's principal executive offices:**

1000 N. WEST STREET, SUITE 1200, 1000 N. WEST STREET, SUITE 1200, WILMINGTON, DELAWARE, 19801.

**Item 2.**

**(a) Name of person filing:**

This Schedule 13G is being filed jointly by: (i) Sands Capital Life Sciences Pulse Fund II, L.P. ("Sands Pulse Fund II"), with respect to the shares of Common Stock held by it; (ii) Sands Capital Alternatives, LLC ("Sands Capital Alternatives"), the investment manager of Sands Pulse Fund II, with respect to the shares of Common Stock held by Sands Pulse Fund II; and (iii) Frank M. Sands ("Sands"), with respect to the shares of Common Stock held by Sands Pulse Fund II. Sands Pulse Fund II, Sands Capital Alternatives and Sands are together referred to herein as the "Reporting Persons".

Sands Capital Life Sciences Pulse Fund II-GP, L.P. ("Sands Pulse GP LP") is the general partner of Sands Pulse Fund II. Sands Capital Life Sciences Pulse Fund-GP, LLC ("Sands Pulse GP LLC" and, together with Sands Pulse GP LP, the "Sands General Partners") is the general partner of Sands Pulse GP LP.

Sands Capital Alternatives is the investment manager of Sands Pulse Fund II and thus may be deemed to beneficially own the shares of Common Stock held by Sands Pulse Fund II. Sands holds ultimate voting and investment power over securities held by Sands Pulse Fund II, and thus may be deemed to beneficially own the shares of Common Stock held by Sands Pulse Fund II. Each Reporting Person and the Sands General Partners disclaim beneficial ownership of any securities beyond its pecuniary interest therein.

**(b) Address or principal business office or, if none, residence:**

The principal business address of each of the Reporting Persons and the Sands General Partners is 1000 Wilson Blvd., Suite 3000, Arlington, VA 22209.

**(c) Citizenship:**

Sands Pulse Fund II and Sands Pulse GP LP are organized under the laws of the Cayman Islands. Sands Capital Alternatives and Sands Pulse GP LLC are organized under the laws of Delaware. Sands is a citizen of the United States.

**(d) Title of class of securities:**

Common Stock, \$0.001 par value per share

**(e) CUSIP No.:**

45719W205

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

- Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);**
- Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);**
- Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);**
- Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);**
- An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);**
- An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);**
- A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);**
- A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);**
- A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);**
- A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:**
- Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).**

**Item 4. Ownership**

**(a) Amount beneficially owned:**

See rows 5 through 11 of the cover pages.

The ownership disclosed in rows 5 through 11 of the cover pages does not include a Series A-1 warrant to purchase 5,475,000 shares of Common Stock (the "Series A-1 Warrant") or a Series B-1 warrant to purchase 10,068,120 shares of Common Stock (the "Series B-1 Warrant"), in each case held by Sands Pulse Fund II, each of which was purchased by Sands Pulse Fund II from the Issuer pursuant to that certain securities purchase agreement dated October 9, 2024 between the Issuer and, among certain other institutional and accredited investors, Sands Pulse Fund II (the "Purchase Agreement"). The Series A-1 Warrant is exercisable on the earlier of (a) the 75th calendar day following the initial filing date of the registration statement covering the resale of the shares of Common Stock underlying the Series A-1 warrants and Series B-1 warrants issued pursuant to the Purchase Agreement (the "Warrant Initial Registration Statement") if the Securities and Exchange Commission ("SEC") notifies the Issuer that it will "review" the Warrant Initial Registration Statement and (b) the fifth business day after the date the Issuer is notified (orally or in writing, whichever is earlier) by the SEC that the Warrant Initial Registration Statement will not be "reviewed" or (even if previously subject to review pursuant to clause (a) of this sentence) will not be subject to further review (the "Initial Exercise Date"). The Series B-1 Warrant is exercisable on the Initial Exercise Date, provided that, to the extent exercisable, the Series A-1 Warrant issued to Sands Pulse Fund II has been exercised in full either by Sands Pulse Fund II or its transferee permitted by the terms of the Series A-1 Warrant. The Series A-1 Warrant and the Series B-1 Warrant each provide that the holder of such warrant will not have the right to exercise any portion of such warrant if such holder, together with its affiliates, would beneficially own in excess of 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The Reporting Persons each disclaim beneficial ownership of the shares of Common Stock underlying each of the Series A-1 Warrant and Series B-1 Warrant because neither the Series A-1 Warrant nor the Series B-1 Warrant is exercisable within 60 days of this filing and such date is not determinable at this time.

**(b) Percent of class:**

See rows 5 through 11 of the cover pages. %

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

See rows 5 through 11 of the cover pages.

**(ii) Shared power to vote or to direct the vote:**

See rows 5 through 11 of the cover pages.

**(iii) Sole power to dispose or to direct the disposition of:**

See rows 5 through 11 of the cover pages.

**(iv) Shared power to dispose or to direct the disposition of:**

See rows 5 through 11 of the cover pages.

**Item 5. Ownership of 5 Percent or Less of a Class.**

**Item 6. Ownership of more than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.**

Not Applicable

**Item 8. Identification and Classification of Members of the Group.**

Not Applicable

**Item 9. Notice of Dissolution of Group.**

Not Applicable

**Item 10. Certifications:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Sands Capital Life Sciences Pulse Fund II,  
L.P.**

**Signature:** */s/ Jonathan Goodman*  
**Name/Title:** **Jonathan Goodman, General Counsel of the GP of the  
GP of Sands Capital Life Sciences Pulse Fund II, L.P.**  
**Date:** **02/13/2026**

**Sands Capital Alternatives, LLC**

**Signature:** */s/ Jonathan Goodman*  
**Name/Title:** **Jonathan Goodman, General Counsel**  
**Date:** **02/13/2026**

**SANDS FRANK M.**

**Signature:** */s/ Frank M. Sands*  
**Name/Title:** **Frank M. Sands**  
**Date:** **02/13/2026**

**Comments accompanying signature:** Sands Capital Life Sciences Pulse Fund II, L.P. signed by Sands Capital Life Sciences Pulse Fund II-GP, L.P., its general partner, by Sands Capital Life Sciences Pulse Fund II-GP, LLC, its general partner, by Jonathan Goodman, General Counsel.

**JOINT ACQUISITION STATEMENT  
PURSUANT TO SECTION 240.13d-1(k)**

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

Dated: February 13, 2026

**Sands Capital Life Sciences Pulse Fund II, L.P.**

By: Sands Capital Life Sciences Pulse Fund II-GP, L.P., *its general partner*

By: Sands Capital Life Sciences Pulse Fund II-GP, LLC, *its general partner*

By: /s/ Jonathan Goodman

Name: Jonathan Goodman

Title: General Counsel

**Sands Capital Alternatives, LLC**

By: /s/ Jonathan Goodman

Name: Jonathan Goodman

Title: General Counsel

By: /s/ Frank M. Sands

Name: Frank M. Sands